{
  "docId": "019de075-7a24-71be-ac51-dd13871aea0a",
  "docSlug": "fd7a76edfe86a80da6108d342915286a",
  "documentTitle": "BioAtla | Investor Presentation Deck | 43 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 43,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 7,
  "notes": "BA3021 Ozuriftamab Vedotin",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7a24-71be-ac51-dd13871aea0a/33",
  "deckHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a",
  "deckJsonHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a.json",
  "deckAnchorHref": "/decks/019de075-7a24-71be-ac51-dd13871aea0a#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "*Investigator-initiated trial. NSCLC = non small cell lung cancer",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "175c9864-9d36-4495-b378-37c05fc20ca6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.8,
        "x": 0.1,
        "y": 0.214
      },
      "kind": "table",
      "text": "Indication, Dose, Maximum Patient #. NSCLC, Q2W monotherapy, N ~ 20. NSCLC, Q2W in combo w/ nivolumab, N ~ 20. NSCLC, 3Q4W monotherapy, N ~ 20. Melanoma, Q2W monotherapy, N ~ 20. Melanoma, Q2W in combo w/ nivolumab, N ~ 20. Head and Neck, Q2W monotherapy, N ~ 40. Ovarian*, Q2W in combo w/ durvalumab, N ~ 20.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "472431e7-2cb6-45f9-9910-8481cdfcbd06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Summary of Dosing Regimens for Phase 2 Clinical Studies with CAB-ROR2-ADC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe26f674-5ef3-4590-800a-cc397b7261d5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "acac3c09-b149-4947-b813-a8e0c6ab3a7e",
      "evidence": "table/data: Indication, Dose, Maximum Patient #. NSCLC, Q2W monotherapy, N ~ 20. NSCLC, Q2W in combo w/ nivolumab, N ~ 20. NSCLC, 3Q4W monotherapy, N ~ 20. Melanoma, Q2W monotherapy, N ~ 20. Melanoma, Q2W in combo w/ niv",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 8,
      "beatId": "e2a4fdc0-9030-4acb-8ef9-b3ca594561cc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The deck outlines a clear roadmap for BioAtla's pipeline and milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}